STOCK TITAN

Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Protagonist Therapeutics (Nasdaq: PTGX) will host a conference call on March 10, 2021, at 4:30 PM ET to discuss its Q4 and full year 2020 financial results. The call can be accessed via phone at 1-844-515-9178 (U.S.) or 1-614-999-9313 (International), with conference ID #: 7756175. A live webcast will also be available on the company's website. Protagonist is developing several peptide-based therapeutics, including PTG-300 and PTG-200, currently in various stages of clinical trials.

Positive
  • Protagonist is advancing multiple peptide-based candidates in clinical trials, including PTG-300 and PTG-200.
  • The upcoming conference call shows transparency and engagement with investors.
Negative
  • None.

NEWARK, Calif., March 3, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), today announced it will host a conference call and webcast on Wednesday, March 10 at 4:30 pm ET/1:30 pm PT to discuss its fourth quarter and full year 2020 financial results.

protagonist_therapeutics__inc__logo

Conference Call and Webcast Information

To access the live call, dial 1-844-515-9178 (U.S./Canada) or 1-614-999-9313 (International) and refer to conference ID #: 7756175. A live webcast of the call will also be accessible on the Investors section of the Company's website at www.protagonist-inc.com. The replay will be available on the Company's website approximately two hours after the call.

About Protagonist Therapeutics Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. PTG-300 is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional oral peptide interleukin-23 receptor antagonist candidates are in development: PN-235, in a Phase 1 study, and PN-232, in the late preclinical stage. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. The Company utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms.

Protagonist is headquartered in Newark, California. For further information, please visit www.protagonist-inc.com.

Cision View original content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-announce-fourth-quarter-and-full-year-2020-financial-results-301238814.html

SOURCE Protagonist Therapeutics, Inc.

FAQ

When is Protagonist Therapeutics' next earnings call?

Protagonist Therapeutics will hold its earnings call on March 10, 2021.

What financial results will Protagonist Therapeutics discuss in the call?

They will discuss the fourth quarter and full year 2020 financial results.

How can I access the Protagonist Therapeutics conference call?

You can dial 1-844-515-9178 for U.S. callers or 1-614-999-9313 for international callers, using conference ID #: 7756175.

What clinical trials is Protagonist Therapeutics currently involved in?

Protagonist is involved in multiple trials, including PTG-300 and PTG-200 for various conditions.

Protagonist Therapeutics, Inc

NASDAQ:PTGX

PTGX Rankings

PTGX Latest News

PTGX Stock Data

2.70B
58.91M
1.18%
104.95%
5.1%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEWARK